HCA Healthcare, Inc. 2024 Q2 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. HCA Healthcare, Inc. is a holding company owning and operating 188 hospitals, 123 freestanding surgery centers, and 23 freestanding endoscopy centers across 20 U.S. states and England. The company operates through three geographic groups: National, American, and Atlantic.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Revenues | $17.492 billion | $15.861 billion | $34.831 billion | $31.452 billion |
| Net Income (Attributable to HCA) | $1.461 billion | $1.193 billion | $3.052 billion | $2.556 billion |
| Diluted EPS | $5.53 | $4.29 | $11.47 | $9.14 |
| Operating Cash Flow (6 Months) | $4.440 billion (vs. $4.278 billion prior year) | |||
| Total Debt | $40.880 billion (as of June 30, 2024) | |||
| Cash and Equivalents | $831 million (as of June 30, 2024) | |||
| Adjusted Segment EBITDA | $3.550 billion | $3.056 billion | $6.903 billion | $6.228 billion |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 10.3% in Q2 2024, driven by a 6.0% increase in equivalent admissions and a 4.1% increase in revenue per equivalent admission. Same-facility revenue grew 9.9%.
- Profitability: Net income attributable to HCA increased 22.5% year-over-year in Q2. Operating margins improved as salaries and benefits as a percentage of revenue declined to 43.9% from 45.9% in the prior year, aided by a 25.7% decline in contract labor.
- Volume Trends: Consolidated admissions rose 6.0% and emergency department visits increased 5.3%. However, total surgeries declined 0.3% (consolidated), though inpatient surgeries increased 2.6% while outpatient surgeries declined 1.8%.
- Uncompensated Care: The estimated cost of total uncompensated care rose to $1.072 billion in Q2 2024 from $899 million in Q2 2023, reflecting a 3.5% increase in same-facility uninsured admissions.
- Debt Activity: In February 2024, the company issued $4.5 billion in senior notes to refinance debt and fund general purposes. In March 2024, it repaid $2.0 billion in notes at maturity.
Guidance, Outlook, and Risks
- Capital Expenditures: Planned capital expenditures for 2024 are expected to range between $5.1 billion and $5.3 billion. Projects under construction have estimated additional costs of approximately $4.6 billion over the next five years.
- Share Repurchases: The company repurchased 4.2 million shares in Q2 2024. As of June 30, 2024, $4.228 billion of repurchase authorization remained available under the January 2024 program.
- Dividends: A quarterly dividend of $0.66 per share was declared on July 22, 2024, payable September 30, 2024.
- Risks and Contingencies:
- Regulatory & Tax: The IRS is examining federal tax returns for 2016–2018 and 2019 for certain affiliates. The company faces potential changes in Medicare/Medicaid reimbursement rates and supplemental payment programs.
- Legal: The company is subject to routine litigation, including False Claims Act (qui tam) suits and professional liability claims. Net reserves for self-insured professional liability risks were $1.959 billion.
- Market Risk: Approximately $2.125 billion of debt is subject to variable interest rates. A hypothetical 1% increase in rates would reduce pretax earnings by approximately $21 million annually.
Investor Verification Checklist
- Verify the sustainability of the 25.7% decline in contract labor costs and its impact on future salary expense ratios.
- Monitor the trend in uninsured admissions (up 3.5% same-facility) and the associated rise in uncompensated care costs.
- Review the details of the $4.5 billion debt issuance and the resulting interest rate profile (average effective rate 5.1%).
- Assess the impact of the $213 million gain on the sale of a California hospital facility on the six-month net income.
- Track the resolution of ongoing IRS examinations and potential adjustments to unrecognized tax benefits.